Drug Trial Radar · NCT07314385
NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Jan 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Jan 1, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- National Taiwan University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Trust Bio-sonics, Inc.
- First posted
- Jan 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I study that will enroll patients with pancreatic cancer and liver metastasis who have failed prior gemcitabine-based chemotherapy. Patients will be treated with nanoliposomal irinotecan plus 5-FU and leucovorin and NH002-based sonoporation to the liver metastasis.
Conditions
- Pancreatic Adenocarcinoma Metastatic
- Liver Metastasis
Interventions
nanoliposomal irinotecan+5-FU+leucovorinDrug
nanoliposomal irinotecan 70 mg/m2 5-FU 2400 mg/m2 Leucovorin 400 mg/m2
NH002 (Perflutren Lipid Microspheres) Injectable SuspensionDrug
2.5 microliter per kilogram (body weight) per dose
Aco Apache UltrasoundDevice
echo for sonoporation
Primary outcomes
What the sponsor says the trial is designed to measure.
- AETime frame: within 28 days (Cycle 1)
- MTDTime frame: within 28 days (cycle 1)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Taiwan University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.